HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026 Monotherapy and multi-regimen combination data demonstrate a cytopenia-sparing safety profile, robust CD47 receptor occupancy, and encouraging dose-dependent antitumor activity   HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its […]

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026 Sustained execution and high-impact data across HanchorBio’s next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC   HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at […]

HanchorBio Reports High Objective Response Rate with HCB101 Combination in   Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.